Hoth Therapeutics, Inc. (HOTH)
NASDAQ: HOTH · Real-Time Price · USD
1.280
-0.020 (-1.54%)
Jul 25, 2025, 4:00 PM - Market closed
Hoth Therapeutics Employees
As of December 31, 2024, Hoth Therapeutics had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,172,536
Market Cap
16.91M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 0 | - |
| Dec 31, 2022 | 3 | -2 | -40.00% |
| Dec 31, 2021 | 5 | 1 | 25.00% |
| Dec 31, 2020 | 4 | 2 | 100.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
HOTH News
- 4 days ago - Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins - PRNewsWire
- 4 weeks ago - Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease. - PRNewsWire
- 4 weeks ago - Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects - PRNewsWire
- 4 weeks ago - Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy - PRNewsWire
- 5 weeks ago - Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth - PRNewsWire
- 5 weeks ago - Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway - PRNewsWire
- 5 weeks ago - Hoth Therapeutics to Attend 2025 BIO International Convention - PRNewsWire
- 6 weeks ago - Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases - PRNewsWire